Background and purpose: Distal involvement of autonomic nerve fibers is critical in familial amyloid polyneuropathy (FAP) due to transthyretin (TTR) mutation. This study compares different methods for assessing autonomic foot innervation in TTR-FAP patients. Methods: Three groups of seven TTR-FAP patients were included, according to disease severity: clinically asymptomatic, moderate or advanced neuropathy. The autonomic investigation included the eutectic mixture of local anesthetics test and laser Doppler flowmetry for vasomotor aspects and the SudoscanÒ (measuring electrochemical skin conductance) and NeuropadÒ test for sudomotor aspects. Somatic innervation was assessed by performing nerve conduction studies, quantitative sensory testing [including vibration, cold and warm detection threshold (WDT) measurements] and laser evoked potentials.
Introduction
A number of studies have highlighted the predominant involvement of small sensory and autonomic nerve fibers at an early stage of familial amyloid polyneuropathy (FAP) due to transthyretin (TTR) mutation [1] . Small sensory fiber lesions can be assessed by neurophysiological techniques, such as laser evoked potential (LEP) recording or thermal quantitative sensory testing (QST), or by measuring the intraepidermal nerve fiber density in skin biopsy. Regarding autonomic testing, heart-rate variability and other cardiac autonomic function tests are the most frequently studied in amyloidosis. However, distal autonomic innervation can be explored using either vasomotor aspects with laser Doppler flowmetry (LDF) or imaging, or sudomotor aspects with a variety of techniques such as quantitative sudomotor axon reflex test (QSART), sympathetic skin reflex, electrochemical skin conductance (ESC) or quantitation of sweat glands in skin biopsy. Literature references for these tests are presented in Appendix S1.
Because of the recent development of new treatment options in TTR-FAP that are mostly beneficial at an early stage of the disease [2] [3] [4] [5] [6] , improving the sensitivity of objective measures is a major challenge. In its last recommendations, the European network ATTReuNET includes autonomic tests, such as heart-rate variability and ESC, in the core monitoring of asymptomatic carriers [7] .
Our study aimed at comparing the value of different tests to assess the autonomic innervation of the foot in the context of TTR-FAP. Vasomotor aspects were explored by visualizing the local vasoconstriction produced by cutaneous application of a eutectic mixture of local anesthetics (EMLA) and measuring heatevoked skin blood flow changes by LDF. Sudomotor reactivity was assessed by measuring ESC with the SudoscanÒ and performing a NeuropadÒ test. Autonomic test results were analyzed with respect to clinical evaluation and neurophysiological investigation of motor and large and small sensory fibers, using a nerve conduction study (NCS), QST and LEP recording.
Methods
This study (SNA-DOU protocol) was carried out in the university hospital Henri Mondor, Cr eteil, France. It was conducted in accordance with the Declaration of Helsinki. The study was approved by our local ethical committee, and all patients signed a written consent. During a period of 1 year (2016-2017), 21 Caucasian patients were recruited, including seven asymptomatic carriers, seven patients with mild to moderate TTR-FAP and seven patients with advanced to severe TTR-FAP. Exclusion criteria were pregnancy, cognitive impairment, methemoglobinemia, hepatic insufficiency and antiarrhythmic agent intake.
Detailed methods are presented in Appendix S1. Briefly, the clinical variables were (i) patient's age; (ii) gender; (iii) body mass index (BMI) (in kg/m²); (iv) Neuropathy Impairment Score (NIS); (v) modified Polyneuropathy Disability Score (mPND); and (vi) Karnofsky performance status.
Four autonomic tests were performed at the right foot. For the EMLA test, wrinkling of the pulp of the big toe was graded 30 min after the application of EMLA cream from 0 (no wrinkling) to 2 (normal). For LDF, the baseline flow at rest (rF) and peak flow during heating (hF), expressed in perfusion units (PU), were measured, and the ratio between these two values (hF/rF) was calculated. In addition, the time to return to baseline (TtR, in s) was recorded during the cooling passive phase. The test was considered abnormal if any of these four variables was altered, according to the following normal limits: rF ≥7 PU, hF ≥17 PU, hF/rF >1.5 and TtR <110 s. For the Sudoscan, the plantar ESC (in lS) was recorded, with normal limit ≥67 lS. For the Neuropad test, a three-grade scale was used: 0 = absent sweating (blue patch), 1 = reduced sweating (mixture of blue and pink), and 2 = normal sweating (pink patch).
Neurophysiological tests include amplitude measurement of distal compound muscle action potentials (CMAPs) for the peroneal and tibial nerves and sensory nerve action potentials (SNAPs) for the superficial peroneal and sural nerves. Normal limits were ≥3/ 5 mV for the peroneal or tibial CMAPs and ≥10/ 20 lV for the peroneal or sural SNAPs. Detection thresholds for vibration (VDT) (lm) and cold and warm stimuli (CDT and WDT) (°C) were measured using the methods of limits with normal limits ≤12.6 lm, 10.5°C and 8.4°C for VDT, WDT and CDT, respectively. Finally, peak-to-peak amplitude of the main N2-P2 complex of the LEPs produced by Nd:YAP laser stimulation was measured at the vertex with normal limit ≥13 lV.
For statistical analyses (detailed in Appendix S1), our series of patients were divided into three groups of seven patients according to the clinical severity of the disease: (i) clinically asymptomatic, with NIS = 0 and mPND = 0; (ii) moderate neuropathy, with NIS <50 and mPND = 1-2; (iii) advanced neuropathy, with NIS >50 and mPND = 3-4.
Results
General demographic, clinical and neurophysiological data in the three groups of patients are presented in Table 1 . The neurophysiological results are presented as binary variables (normal/abnormal) in Table 2 . The main result is that the EMLA test grade and the LDF parameters did not differ between groups in contrast to all the other neurophysiological tests (sudomotor tests, NCS, QST and LEP).
In group 1 (clinically asymptomatic carriers), three patients had an altered EMLA test and LDF, one patient had altered EMLA and Neuropad tests, one patient had altered LDF only and one patient had altered Sudoscan, Neuropad and WDT. Only one patient had all normal tests.
In group 3 (clinically advanced neuropathy), all neurophysiological tests were altered, except both the EMLA test and LDF in one patient, only the EMLA test in one patient and the CDT in two patients. In detail, in this group ESC ranged between 7 and 41 lS, the 15-min Neuropad grade was 1 (mixed color patch) in six patients and 0 (fully blue patch) in one patient, the peroneal and tibial CMAPs were absent except in two patients, the peroneal and sural SNAPs were absent except in one patient, the VDT was maximal (25 lm) in all patients, the WDT was maximal (18°C) in three patients and LEPs were absent in all patients.
No influence of gender or the type of TTR mutation was found on any neurophysiological variable (P values between 0.10 and 0.94), except a lower CMAP amplitude in patients with Val30Met versus nonVal30Met mutation (mean AE SD 2.9 AE 4.0 vs. 7.0 AE 4.8, P = 0.003, Mann-Whitney test).
Patient age correlated negatively only with ESC (r = À0.66, P = 0.001, Spearman test) and tended to correlate with LEP amplitude (r = À0.59, P = 0.005) but not with the other neurophysiological variables (r between À0.54 and 0.11, P between 0.01 and 0.87). Conversely, all neurophysiological results correlated Table 1 General demographic, clinical and neurophysiological data in the three groups of seven patients with TTR mutation, according to the clinical presentation: asymptomatic (group 1), moderate neuropathy (group 2), advanced neuropathy (group 3)
Val30Met (7) Age at disease onset (years) -54. with NIS (r ranging between À0.88 and À0.66, P < 0.005, Spearman test) except CDT (r = 0.58, P = 0.006).
Discussion
The sudomotor tests (Sudoscan and Neuropad) but not the vasomotor tests (EMLA test and LDF) were found to be sensitive to distinguish between clinically asymptomatic carriers and patients with either moderate or advanced TTR-FAP. Regarding vasomotor tests, it must be highlighted that the EMLA test was performed at the toe for the first time, whereas it is usually performed at the digits [8] . It was thought that performing this test at the toe should increase its diagnostic value in the context of a length-dependent neuropathy, such as TTR-FAP. However, skin wrinkling is more difficult to assess at the pulp of the toes than of the digits. At finger level a five-point scale has been published [9, 10] , but at the toe only three grades of wrinkling have been distinguished: absent (grade 0), partial (grade 1) and normal (grade 2). Even using this simplified three-point scale the test was found to be unreliable, since for instance normal wrinkling was found in two patients with advanced neuropathy but none in patients with moderate neuropathy.
With regard to LDF, first it should be mentioned that this test is much more time-consuming than the other tests, especially ESC measurement with Sudoscan, which is very quick. The LDF technique provides several variables. The rF and hF values were abnormal in up to one or two patients in the different groups and clearly lacked sensitivity. The ratio hF/rF performed better since it was abnormal in one patient in groups 1 and 2 but in four patients of group 3. In contrast, the TtR was abnormal in three patients in groups 1 and 2 but only in one patient of group 3. Even if the results were analyzed only using the hF/rF variable, LDF did not show good diagnostic performance. This is clearly explained by a large inter-individual variability, as previously acknowledged [11] . In the present study, LDF assessment was performed in response to local heating but other provocative procedures may be applied, either local, such as painful electrical stimulation or acetylcholine iontophoresis, or general, such as deep inspiration or standing. Only very few studies have assessed the value of LDF methods in amyloid neuropathy: vasomotor changes were measured with LDF in response to deep inspiration in 11 patients with TTR-FAP [12] and to standing in six patients with TTR-FAP [13] , whilst one study investigated local vasodilatation in response to acetylcholine and sodium nitroprusside iontophoresis at upper limb level in seven patients with amyloid light-chain amyloidosis [14] . More recently, it was proposed to analyze the vasomotor axon reflex triggered by C-fibers by using laser Doppler imaging rather than LDF [15] [16] [17] [18] . The quantification of the neurogenic flare response by laser Doppler imaging is a very promising technique to assess the existence of small-fiber neuropathy with less intra-and inter-individual variability than LDF, although the methods for image analysis remain to be standardized [11, 19] .
The fact that the two tests used to assess vasomotor responses at the level of the foot were not relevant for the diagnosis of TTR-FAP certainly does not mean that these types of small autonomic vasomotor fibers are spared in this clinical condition. This observation rather results from the technical inaccuracy of the techniques used. Other techniques are awaited to specifically assess the distal vasomotor changes in TTR-FAP, which have potentially great clinical impact (e.g. regarding wound healing at the extremities). The laser Doppler imaging flare is probably one of the most promising techniques of investigation in this context.
Regarding sudomotor tests, our results were much more encouraging. The Neuropad test is simple and does not need any specific machine. Therefore, it can be used in a routine clinical setting. In the present Because of the unreliability of the latter test, it is difficult to decide between a false-negative result and a high sensitivity of the Neuropad test. In patients of groups 2 and 3, the Neuropad test was always abnormal, but the absence of sweating (grade 0) was found in only one patient in both groups 2 and 3. All the other patients had intermediate grade (grade 1) showing partial sweating. This observation clearly illustrates the limitations of this test. First, the test does not allow a fine grading of the evolution of the neuropathy when using a three-grade scale defined on visual inspection. Automated quantification of the percentage of color change into pink using image analysis software has recently been proposed to improve the sensitivity of the Neuropad test [20] . Secondly, at the 15-min assessment time, only a few patients still show an absence of sweating (grade 0). Therefore, a shorter assessment time might be interesting. In this study, the color of the patch after 10 min of cutaneous plantar application was also assessed. At this time, the test better discriminated patients between groups 2 and 3 (1/7 vs. 5/7 patients with grade 0, respectively) but was not accurate to provide an early marker of neuropathy in asymptomatic carriers who all showed an intermediate grade 1 corresponding to partial sweating. This gain in sensitivity but loss in specificity at a shorter time of assessment was reported previously [21] [22] [23] . The initial technique of the Neuropad test was to measure the time required for complete color change, i.e. for the Neuropad to become fully blue, but it could take more than 30 min in patients with severe neuropathy [21, [24] [25] [26] [27] [28] . This method was not applied in the present study, so no conclusions can be drawn. However, the approach complicates the realization of the Neuropad test because it means that the color changes of the patch have to be continuously monitored for a long time, up to at least 30 min, with a precision of 10 s. The method used, simply consisting of looking at the color of the patch at a precise time point, is much more suitable for clinical practice. With this method, our study shows that Neuropad may be valuable for detecting early TTR-FAP but has much less interest in the follow-up of an overt neuropathy.
Regarding the measurement of ESC by Sudoscan, the sensitivity to detect abnormal sweating in asymptomatic carriers could be lower than for the Neuropad test (1/7 vs. 2/7 abnormal results, respectively), but detected alterations may be more specific. In any case, the major advantages of the Sudoscan technique are that it is very quick (2-3 min to evaluate the four extremities concomitantly) and very convenient for the follow-up. Indeed, it provides continuous quantitative data (in contrast to the Neuropad test), showing very good correlation with the clinical progression of the neuropathy. Thus, ESC was divided on average by 30% between patients of group 2 and group 1 and by 63% between patients of group 3 and group 2. Its value was found comparable to the measurement of intraepidermal nerve fiber density and correlated to QSART at the foot [29] . Its specific use in the evaluation of TTR-FAP has been the subject of only few publications [30] [31] [32] but of a recommendation of use by a consensus group [7] .
Finally, some comments should be made regarding the other neurophysiological tests performed in this study. First, large-fiber parameters were found to be insensitive (NCS and VDT) to detect early neuropathy in asymptomatic carriers. This was obviously expected, since TTR-FAP is clearly a predominant small-fiber neuropathy at its onset. However, largefiber variables (CMAP and SNAP amplitudes and VDT) were found to be discriminant to gradually follow the progression of the neuropathy, being altered in 28%-57% of patients of group 2 and in 100% of patients of group 3. Regarding small-fiber variables, WDT and LEP clearly performed better than CDT, which was the only NCS/QST parameter not significantly correlated with NIS values. Actually, CDT remained within normal values in two patients of group 3 with advanced neuropathy. Our results suggest limiting the investigation of small-diameter sensory nerve fibers to WDT and LEP recording, as was concluded in a previous work [33] . The fact that one asymptomatic carrier showed highly probable early TTR-FAP with altered Sudoscan, Neuropad and WDT but normal LEPs is in favor of a C-fiber predominant neuropathy, relatively respecting Ad fibers.
Before concluding, some limitations of this study must be acknowledged. First, as aforementioned, alternative methods could have been used. For example, the EMLA test was not performed as usual at the level of the fingers, the vasomotor reactivity was assessed by LDF in response to local heating only, and the time required for complete color change was not monitored during the Neuropad test. In addition, other techniques to evaluate distal sudomotor or vasomotor innervation, such as QSART or laser Doppler imaging flare, were not included in this study.
Secondly, beyond clinical severity, the three groups of patients also differed according to the type of TTR mutation and patient age. Compared to the patients with non-Val30Met mutation, the patients with Val30-Met mutation had lower CMAP amplitude, but they were the only ones to constitute the group 3 with advanced neuropathy. Regarding patient age, an influence was found on ESC and LEP amplitude but not on the other neurophysiological variables. In contrast, the NIS correlated with all neurophysiological results. Thus, although the patients with advanced neuropathy were significantly older, the neurophysiological results overall appeared to reflect the clinical severity of the disease rather than the age of the patients. Finally, gender did not differ between patient groups and had no influence on neurophysiological outcomes.
The most important limitations, however, are the small sample size, even if patients were evenly distributed according to clinical severity, and especially the absence of clinical scoring of dysautonomia. There are various validated clinical scales and questionnaires to evaluate the symptoms of autonomic dysfunction, such as the 31-question Composite Autonomic Symptom Scale 31 (COMPASS 31) [34, 35] , derived from the 169-item Autonomic Symptom Profile [36] or the Compound Autonomic Dysfunction Test, which was developed in the context of TTR-FAP [37] . However, these scales rather assess a context of general dysautonomia, whilst the goal of this study was to evaluate focal dysautonomia at the extremities. Nevertheless, some clinical evaluation of this aspect, even subjective and non-validated, should have been added.
In conclusion, this study showed the value of two sudomotor tests (ESC measurement by Sudoscan and the Neuropad test) in the investigation of TTR-FAP. In particular, the Neuropad test could be used to provide an early marker of neuropathy onset but requiring a confirmation by ESC measurement. On the other hand, ESC measurement, but not the Neuropad test (at least assessed at a fixed time point), appears to be valuable to follow the progression of the neuropathy. In addition to these tests assessing autonomic nerve fibers, the small-diameter sensory fibers must also be evaluated, and for this purpose WDT and LEP recording appear to be relevant, both for providing an early marker of TTR-FAP onset and for follow-up. Followup investigation should also include large-fiber assessment techniques, i.e. NCS and VDT measurement. Regarding vasomotor innervation of the extremities, the two tests included in this study, i.e. the EMLA test performed at the big toe and LDF measurement to local heating, were found to provide unreliable data. This leaves room for other techniques, such as laser Doppler imaging, to evaluate this type of autonomic innervation, alteration of which may have major clinical repercussion in patients with TTR-FAP.
